The FDA on May 15, 2024, granted accelerated approval to BREYANZI® for adults with relapsed or refractory Follicular Lymphoma (FL) who have received two or more prior lines of systemic therapy. BREYANZI® is a product of Juno Therapeutics, Inc.
Bottom Ad
Advertisement
Subscribe
